Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMP NASDAQ:ANIX NASDAQ:NERV NASDAQ:OTIC NASDAQ:ZYNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsANIXAnixa Biosciences$3.30-2.1%$3.12$2.07▼$4.20$108.63M0.58109,041 shs175,981 shsNERVMinerva Neurosciences$2.03-1.5%$2.10$1.15▼$2.87$14.19M-0.2515,530 shs9,901 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/AZYNEZynerba Pharmaceuticals$1.30$1.30$0.25▼$1.40$70.12M1.32515,333 shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ANIXAnixa Biosciences0.00%+12.63%+11.86%-2.37%-4.35%NERVMinerva Neurosciences0.00%-5.36%-15.77%+13.09%-28.77%OTICOtonomy0.00%0.00%0.00%0.00%0.00%ZYNEZynerba Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsANIXAnixa Biosciences$3.30-2.1%$3.12$2.07▼$4.20$108.63M0.58109,041 shs175,981 shsNERVMinerva Neurosciences$2.03-1.5%$2.10$1.15▼$2.87$14.19M-0.2515,530 shs9,901 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/AZYNEZynerba Pharmaceuticals$1.30$1.30$0.25▼$1.40$70.12M1.32515,333 shsN/A(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ANIXAnixa Biosciences0.00%+12.63%+11.86%-2.37%-4.35%NERVMinerva Neurosciences0.00%-5.36%-15.77%+13.09%-28.77%OTICOtonomy0.00%0.00%0.00%0.00%0.00%ZYNEZynerba Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis Pharmaceuticals 0.00N/AN/AN/AANIXAnixa Biosciences 3.00Buy$9.00172.73% UpsideNERVMinerva Neurosciences 2.00Hold$5.00146.31% UpsideOTICOtonomy 0.00N/AN/AN/AZYNEZynerba Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OTIC, ADMP, ANIX, NERV, and ZYNE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025ANIXAnixa BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.009/9/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/19/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/5/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 9/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00ANIXAnixa Biosciences$210K517.31N/AN/A$0.47 per share7.02NERVMinerva NeurosciencesN/AN/A$0.21 per share9.71($3.67) per shareN/AOTICOtonomy$130K4.48N/AN/A$0.97 per share0.01ZYNEZynerba PharmaceuticalsN/AN/AN/AN/A$1.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/AANIXAnixa Biosciences-$12.55M-$0.35N/A∞N/AN/A-67.45%-59.18%N/ANERVMinerva Neurosciences$1.44M$1.481.37N/AN/AN/A-41.35%31.37%11/4/2025 (Estimated)OTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/AZYNEZynerba Pharmaceuticals-$35.04M-$0.80N/AN/AN/AN/A-90.03%-72.62%N/ALatest OTIC, ADMP, ANIX, NERV, and ZYNE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/10/2025Q3 2025ANIXAnixa Biosciences-$0.10-$0.07+$0.03-$0.07N/AN/A8/14/2025Q2 2025NERVMinerva Neurosciences-$0.95-$0.43+$0.52-$0.43N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AANIXAnixa BiosciencesN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/AZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19ANIXAnixa BiosciencesN/A8.458.45NERVMinerva NeurosciencesN/A6.156.15OTICOtonomyN/A1.741.74ZYNEZynerba PharmaceuticalsN/A3.433.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%ANIXAnixa Biosciences29.13%NERVMinerva Neurosciences34.56%OTICOtonomy41.23%ZYNEZynerba Pharmaceuticals11.23%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%ANIXAnixa Biosciences25.30%NERVMinerva Neurosciences8.60%OTICOtonomy1.09%ZYNEZynerba Pharmaceuticals13.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableANIXAnixa Biosciences532.92 million24.59 millionOptionableNERVMinerva Neurosciences96.99 millionN/ANot OptionableOTICOtonomy5168.53 million67.78 millionOptionableZYNEZynerba Pharmaceuticals2553.94 million46.91 millionOptionableOTIC, ADMP, ANIX, NERV, and ZYNE HeadlinesRecent News About These CompaniesFragile X Syndrome Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Novartis, Neuren Pharma, Roche, Seaside Therapeutics, Inc., Marinus ...August 28, 2025 | theglobeandmail.comEurope’s cannabis pharmaceuticals market matures amid cautious investmentAugust 4, 2025 | finance.yahoo.com22q11.2 Deletion Syndrome Market Research Report 2025: Zynerba Pharmaceuticals is at the Forefront with Its Clinical-stage Therapy Zygel (ZYN002)June 25, 2025 | globenewswire.comHarmony Biosciences: If It Ain't BrokeJune 5, 2025 | seekingalpha.comUS Penny Stocks To Watch In October 2024October 28, 2024 | uk.finance.yahoo.comDiscover 3 US Penny Stocks With Market Caps Over $70MOctober 24, 2024 | uk.finance.yahoo.comAtea Pharmaceuticals Leads The Charge In US Penny Stocks SpotlightOctober 22, 2024 | uk.finance.yahoo.comGW Pharma's cannabis-derived epilepsy drug approved in EUOctober 7, 2024 | pharmaphorum.comPFragile X Syndrome Therapeutic Pipeline Research Report 2024 Featuring Zynerba, Tetra Discovery Partners, Nova Mentis, Neuren Pharmaceuticals, and Tetra Discovery PartnersJuly 31, 2024 | globenewswire.comHarmony Biosciences Reports Strong Third Quarter 2023 Financial ResultsOctober 31, 2023 | finance.yahoo.comWhy Shares of Harmony Bioscience Are Falling on FridayOctober 13, 2023 | fool.comNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder TherapiesOctober 11, 2023 | markets.businessinsider.comHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEOctober 11, 2023 | finance.yahoo.comH.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)October 10, 2023 | knoxdaily.comKAnalysts: ZYNE stock price target of $1.25 in 12 monthsOctober 5, 2023 | knoxdaily.comKImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and InstructionsOctober 4, 2023 | finance.yahoo.comExamining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)October 2, 2023 | knoxdaily.comK20 Countries With Highest Rate of EpilepsySeptember 29, 2023 | finance.yahoo.comZynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023September 29, 2023 | finance.yahoo.comHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealSeptember 27, 2023 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Uber Eats Partnership Fueling Serve Robotics' GrowthBy Jeffrey Neal Johnson | August 28, 2025AEHR Spikes 36% on Hyperscaler Order—Investors Should Take NoticeBy Leo Miller | August 27, 20253 Under-the-Radar Biotechs Under $5 That Could Soar 200%By Chris Markoch | September 9, 2025Reddit Hits Record Highs: Why Wall Street Is Taking NoticeBy Jeffrey Neal Johnson | September 15, 2025These 3 Tech Stocks Just Supercharged Their BuybacksBy Leo Miller | September 16, 2025OTIC, ADMP, ANIX, NERV, and ZYNE Company DescriptionsAdamis Pharmaceuticals NASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Anixa Biosciences NASDAQ:ANIX$3.30 -0.07 (-2.08%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$3.33 +0.03 (+0.91%) As of 09/19/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Minerva Neurosciences NASDAQ:NERV$2.03 -0.03 (-1.46%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$2.00 -0.03 (-1.43%) As of 09/19/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Otonomy NASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.Zynerba Pharmaceuticals NASDAQ:ZYNEZynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
